Volume | 547,669 |
|
|||||
News | - | ||||||
Day High | 20.70 | Low High |
|||||
Day Low | 19.81 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Veracyte Inc | VCYT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
19.88 | 19.81 | 20.70 | 19.81 | 19.85 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
9,772 | 547,669 | $ 20.25 | $ 11,092,208 | - | 18.61 - 30.52 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:25 | priorref | 141 | $ 19.83 | USD |
Veracyte Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.5B | 75.07M | - | 361.05M | -74.4M | -0.99 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Veracyte News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VCYT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 19.30 | 20.70 | 18.61 | 19.29 | 826,504 | 0.53 | 2.75% |
1 Month | 21.38 | 22.35 | 18.61 | 20.28 | 648,316 | -1.55 | -7.25% |
3 Months | 26.76 | 26.83 | 18.61 | 22.35 | 681,056 | -6.93 | -25.90% |
6 Months | 20.63 | 29.35 | 18.61 | 23.88 | 650,505 | -0.80 | -3.88% |
1 Year | 23.05 | 30.52 | 18.61 | 24.40 | 620,298 | -3.22 | -13.97% |
3 Years | 49.81 | 54.13 | 14.85 | 27.48 | 749,707 | -29.98 | -60.19% |
5 Years | 23.00 | 86.03 | 13.90 | 30.72 | 697,448 | -3.17 | -13.78% |
Veracyte Description
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product. |